risvutatug rezetecan

all catalysts(1)

News(10)

• Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
  Merck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Ca…
  biospace · 10d ago
• Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
  Daiichi Sankyo and Merck & Co. have withdrawn an antibody-drug conjugate (ADC) filing after the FDA said they lacked the data for accelerated approval in a lung cancer population.
  fiercebiotech · 10d ago
• GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
  After inking a T cell engager pact with Chimagen Biosciences a few years ago, GSK is back for more, this time acquiring a multiple myeloma program from the antibody specialist.
  biospace · 23d ago
• GSK lays off 650 staffers amid closure of German vaccine manufacturing site
  GSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid the pharma’s recent $2.5 billion savings campaign.
  biospace · 23d ago
• Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
  BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place in South Korea. These companies and their partners have all shared new fi…
  biospace · 24d ago
• GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck
  GSK’s risvutatug rezetecan has achieved a median overall survival of 18.5 months in a phase 3 trial, painting the antibody-drug conjugate as a threat to Amgen and Merck & Co. in the lung cancer field.
  fiercebiotech · 27d ago
• GSK shares rise as $2.5B cost-cutting plan unveiled
  As GSK records $2.4 billion in impairment charges for the second quarter, the U.K. pharma has announced a sweeping restructure designed to save about the same amount of money over the next few years.
  biospace · 2mo ago
• GSK partner Hansoh reports another phase 3 win for priority ADC
  Hansoh Pharmaceutical has guided its GSK-partnered, B7-H3-directed antibody-drug conjugate to another phase 3 win in China.
  fiercebiotech · 2mo ago
• GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
  Jideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer as…
  biospace · 2mo ago
• GSK, Hansoh ADC extends survival in lung cancer study
  GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.
  biopharma_dive · 3mo ago